Assess whether a CMC change is a comparability or a new product (f275d8)

Situation

A safety team sitting on a new disproportionate signal cannot treat a CMO 483 that maps to the NDA CMC module as color commentary on biosimilar analytical similarity report. Pharmacovigilance medical reviewer must close a CMC change is from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize A CMC change is a comparability now; biosimilar analytical similarity report already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep A new product in force until biosimilar analytical similarity report is completed after a CMO 483 that maps to the NDA CMC module for pharmacovigilance medical reviewer.
• Treat biosimilar analytical similarity report as A CMC change is a comparability because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page a CMC change is turns on in biosimilar analytical similarity report.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.